The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
-
Paragraph 0265-0268
(2021/03/19)
Structure-activity studies of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes: A novel class of highly potent nicotinic receptor ligands
The potential for nicotinic ligands with affinity for the α4β2 or α7 subtypes to treat such diverse diseases as nicotine addiction, neuropathic pain, and neurodegenerative and cognitive disorders has been exhibited clinically for several compounds while p
Breining, Scott R.,Melvin, Matt,Bhatti, Balwinder S.,Byrd, Gary D.,Kiser, Melanie N.,Hepler, Christopher D.,Hooker, Dawn N.,Zhang, Jenny,Reynolds, Leslie A.,Benson, Lisa R.,Fedorov, Nikolai B.,Sidach, Serguei S.,Mitchener, J. Pike,Lucero, Linda M.,Lukas, Ronald J.,Whiteaker, Paul,Yohannes, Daniel
p. 9929 - 9945
(2013/01/16)
More Articles about upstream products of 28232-65-7